This is a U.S. news story, published by CNBC, that relates primarily to Moderna news.
For more U.S. news, you can click here:
more U.S. newsFor more Moderna news, you can click here:
more Moderna newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
seasonal Covid vaccine market. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Covid vaccine supply news, new products news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Covid vaccine supply contractCNBC
•
85% Informative
Moderna has slashed its full-year sales guidance, citing lower sales in Europe , a "competitive environment" for respiratory vaccines in the U.S. The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 billion , down from $4 billion .
Its shares are up nearly 20% this year on increasing confidence around its pipeline.
VR Score
91
Informative language
93
Neutral language
83
Article tone
semi-formal
Language
English
Language complexity
47
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links